Vanda Pharmaceuticals earnings were -$274.9M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest VNDA earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$62.5M, up 28.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VNDA reported annual earnings of -$220.5M, with 1,066.5% growth.
Vanda Pharmaceuticals Earnings Reports & History FAQ
What were Vanda Pharmaceuticals's earnings last quarter?
On VNDA's earnings call on Aug 5, 2026, Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 2026 earnings per share (EPS) of -$1.04, up 126.09% year over year. Total VNDA earnings for the quarter were -$62.51 million. In the same quarter last year, Vanda Pharmaceuticals's earnings per share (EPS) was -$0.46.
Is Vanda Pharmaceuticals profitable or losing money?
As of the last Vanda Pharmaceuticals earnings report, Vanda Pharmaceuticals is currently losing money. Vanda Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$274.85 million, a 310.61% increase year over year.
What was VNDA's earnings growth in the past year?
As of Vanda Pharmaceuticals's earnings date in Aug 5, 2026, Vanda Pharmaceuticals's earnings has grown year over year. VNDA earnings in the past year totalled -$274.85 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.